Kura Oncology, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 130.47 million compared to USD 89.63 million a year ago. Basic loss per share from continuing operations was USD 1.97 compared to USD 1.69 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19 USD | +1.33% | +7.47% | +32.13% |
Apr. 22 | Sector Update: Health Care Stocks Advance Premarket Monday | MT |
Apr. 22 | Kura Oncology Gets Breakthrough Designation For Leukemia Therapy | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.13% | 1.45B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021